Gene and Protein Information
Species	TM	AA	Chromosomal Location	Gene Symbol	Gene Name	Reference
Human	-	2351	Xq28	F8	coagulation factor VIII
Mouse	-	2319	X 38.17 cM	F8	coagulation factor VIII
Rat	-	-	18p13	F8	coagulation factor VIII

Previous and Unofficial Names

coagulation factor VIII, procoagulant component | FVIII | HEMA

Database Links
Alphafold	P00451 (Hs), Q06194 (Mm)
CATH/Gene3D	2.60.120.260, 2.60.40.420
ChEMBL Target	CHEMBL3143 (Hs)
DrugBank Target	P00451 (Hs)
Ensembl Gene	ENSG00000185010 (Hs), ENSMUSG00000031196 (Mm), ENSRNOG00000031197 (Rn)
Entrez Gene	2157 (Hs), 14069 (Mm), 302470 (Rn)
Human Protein Atlas	ENSG00000185010 (Hs)
KEGG Gene	hsa:2157 (Hs), mmu:14069 (Mm), rno:302470 (Rn)
OMIM	300841 (Hs)
Orphanet	ORPHA121677 (Hs)
Pharos	P00451 (Hs)
RefSeq Nucleotide	NM_000132 (Hs), NM_007977 (Mm), NM_183331 (Rn)
RefSeq Protein	NP_000123 (Hs), NP_032003 (Mm), NP_899160 (Rn)
UniProtKB	P00451 (Hs), Q06194 (Mm)
Wikipedia	F8 (Hs)

Selected 3D Structures
	Description:  Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. PDB Id:  3CDZ Resolution:  3.98Å Species:  Human References:  3

Download all structure-activity data for this target as a CSV file

Inhibitors
Key to terms and symbols		Click column headers to sort
Ligand Sp. Action Value Parameter Reference drotrecogin alfa Hs Inhibition - - 1-2 ⤷ Antithrombotic effect thought to occur via inhibition of factors Va and VIIIa [1-2]

Clinically-Relevant Mutations and Pathophysiology
Disease:  Factor VIII deficiency Disease Ontology: DOID:12134 OMIM: 134500
Disease:  Mild hemophilia A Synonyms: Hemophilia A; HEMA [OMIM: 306700] OMIM: 306700 Orphanet: ORPHA169808
Disease:  Moderately severe hemophilia A Synonyms: Hemophilia A; HEMA [OMIM: 306700] OMIM: 306700 Orphanet: ORPHA169805
Disease:  Severe hemophilia A Synonyms: Hemophilia A; HEMA [OMIM: 306700] OMIM: 306700 Orphanet: ORPHA169802
Disease:  Symptomatic form of hemophilia A in female carriers Orphanet: ORPHA177926

General Comments
Recombinant factor VIII (Voncento®) is used to treat hemophilia A and von Willebrand diseases. A long-acting recombinant FVIII-Fc fusion protein (efanesoctocog alfa; ALTUVIIIO®) has been approved as a treatment for hemophilia A.